Clinical Trials on PI3Kδ Inhibitor in France

Total 71 results

Groupe Hospitalier Paris Saint Joseph

Completed

Evaluation of the Long-term Tolerance of Proton Pump Inhibitor (PPI) Discontinuation in Geriatric Patients Treated With Long-term Therapy Without a Recognized Indication (EGERIPP 2)

Proton Pump Inhibitor

France
Groupe Hospitalier Paris Saint Joseph

Completed

Evaluation of Rebound Effect After Withdrawal of Proton Pump Inhibitor in Geriatric Population

Proton Pump Inhibitor

France
Groupe Hospitalier Pitie-Salpetriere
Vanderbilt University Medical Center

Completed

Identification of PAthways of Kinase Inhibitors TOxicity (PAKITO)

Kinase Inhibitors Toxicity

France
Institut Mutualiste Montsouris
Institut Curie

Recruiting

Troponin to Detect Major Cardiovasculaire Advserse Events on Immune Checkpoint Inhibitors (TILT)

Cancer | Immune Checkpoint Inhibitor | Cardiovascular Biomarkers

France
Nantes University Hospital

Completed

Efficacy of a Multi-faceted Intervention to Deprescribe Proton Pump Inhibitors (PPI) in Primary Care: a Population-based, Pragmatic, Cluster-randomized Controlled Trial. (DeprescrIPP)

Proton Pump Inhibitors | Deprescription

France
Institut Mutualiste Montsouris

Recruiting

Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors (FAST-TRACK)

Cancer | Cardiovascular Complication | Immune Checkpoint Inhibitor | Immune-related Adverse Event

France
Nantes University Hospital

Completed

Efficacy of a Multi-faceted Intervention Combining an Educational Outreach Visit to General Practitioners and Patient Education Material to Deprescribe Proton Pump Inhibitors (PPI): a Population-based, Pragmatic, Cluster-randomized Controlled Trial (DeprescrIPPDAM)

Proton Pump Inhibitors | Deprescription

France
Fondation Ophtalmologique Adolphe de Rothschild

Completed

Investigation of Potential Retinal Toxicity Associated With Hair Dye Products Containing pPD Type Aromatic Amines (CAPITOX)

MEK Inhibitor-Associated Serous Retinopathy

France
Institut Curie

Recruiting

Development of an EORTC Immune Checkpoint Inhibitor-specific Quality of Life Item List: Phase 1 & 2 (EORTC ICI)

Quality of Life | Cancer | IMMUNE CHECKPOINT INHIBITOR

France
Institut Bergonié
Institut National de la Santé Et de la Recherche Médicale, France

Completed

Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI) (SURROGATE-ICI)

Cancer Treated With Immune-checkpoint Inhibitors

France
Centre Hospitalier Universitaire, Amiens
Central Hospital Saint Quentin

Recruiting

Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment (Ibe2i-TIPCI)

Immunotherapy | Immune Checkpoint Inhibitors | Immune-related Adverse Event | Predictive Biomarkers

France
Groupe Hospitalier Pitie-Salpetriere
Institut Curie

Completed

EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Database (EXIT)

Cancer | Immune Checkpoint Inhibitor-Related Myocarditis | Immune-related Adverse Event

France
Hôpital le Vinatier

Completed

Inhibition Transcranial Random Noise Stimulation (inhibistim)

Impulsive Behavior | Inhibition

France
Centre Hospitalier Universitaire, Amiens

Withdrawn

Clinical Significance of Hepatic Biomarkers in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors (HEPATICI)

Lung Cancer | Immune Checkpoint Inhibitor | Liver Biomarkers | Transaminases

France
University Hospital, Brest

Completed

Thyroid Dysfunction and Nivolumab Reponse in NSCLC (THYRONIVO)

Non Small Cell Lung Cancer Metastatic | Prognosis | Thyroid Dysfunction | Immune Checkpoint Inhibitor | Treatment Adverse Effect

France
Pharvaris Netherlands B.V.

Recruiting

Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema (RAPIDe-2)

Hereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditions

United States, Bulgaria, Czechia, Hungary, Spain, France, Germany, Poland, Canada, Israel
University Hospital, Montpellier

Terminated

The Role of the Coagulation Pathways in Recurrent Angioedema (Angiocoag)

Chronic Spotaneous Urticaria, Idiopathic Non Histaminergic Angioderma, Hereditary Angioedema With C1 Inhibitor Deficiency

France
Novo Nordisk A/S

Completed

Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers

Healthy | Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

France
Assistance Publique - Hôpitaux de Paris

Recruiting

Relationship Between Immunity and Metabolism in Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer. ( RIMEC ) (RIMEC)

Cancer | Immune Checkpoint Inhibitors | Metabolism Disorder

France
University Hospital, Caen

Completed

Delirium Related to Proton Pump Inhibitors Use

Delirium | Hyponatremia | Proton Pump Inhibitor Adverse Reaction

France
University Hospital, Bordeaux

Recruiting

AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE (APPENDAGE)

Stroke | Atrial Fibrillation | Anticoagulants | Platelet Aggregation Inhibitors | Atrial Appendage

France
UNICANCER

Terminated

SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer (SAFIR-PI3K)

Breast Cancer, PI3K, Alpelisib

France
University Hospital, Montpellier
CryoMed Millenaire

Recruiting

Assessment of Cryotherapy's Analgesic Impact in Anti-aromatase-induced Arthralgia (CRYOMATASE)

Breast Cancer | Aromatase Inhibitors

France
MacroGenics

Recruiting

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer Recurrent | Immunotherapy | Androgen-Independent Prostatic Cancer | Androgen-Resistant Prostatic Cancer | Hormone Refractory Prostatic Cancer | Immune Checkpoint Inhibitor | Androgen-Independent Prostatic Neoplasms | Androgen-Insensitive Prostatic Cance | Inhibitory Checkpoint Molecule

United States, Spain, France, Belgium, United Kingdom, Poland, Georgia, Bulgaria, Puerto Rico, Australia
Novo Nordisk A/S

Completed

Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects

Healthy | Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Acquired Bleeding Disorder | Acquired Haemophilia | Congenital FVII Deficiency | Glanzmann's Disease

France
University Hospital, Grenoble
University Hospital, Rouen; University Hospital, Paris

Recruiting

Bradykinin-degradating Enzymes Activities in Angiotensin-Converting Enzyme Inhibitors-associated Angioedema (KIN-ACE)

Angio-Oedema Caused by Angiotensin-Converting-Enzyme Inhibitor

France
Hospices Civils de Lyon

Completed

Pre-operative Exposure to SGLT2 Inhibitors and Post-operative Acute Renal Failure in Cardiac Surgery (SGLT2i-PO-AKI)

Acute Kidney Injury | Cardiac Surgery | Sodium/Glucose Cotransporter Inhibitor 2

France
Institut Curie

Recruiting

LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG (LIBERTYLUNG)

NSCLC Patient in a Metastatic Stage Eligible for First-line Treatment With Immune Checkpoint Inhibitor

France
Blueprint Medicines Corporation

Active, not recruiting

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | EGF-R Positive Non-Small Cell Lung... and other conditions

United States, Canada, Taiwan, Korea, Republic of, Singapore, Japan, United Kingdom, France, Netherlands, Spain
Centre Francois Baclesse
National Cancer Institute, France

Recruiting

Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients (OLA-TMZ-RTE-01)

Radiotherapy | PARP Inhibitor | Malignant Gliomas

France
French Innovative Leukemia Organisation
Bristol-Myers Squibb

Completed

REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy (RESIST)

Small Lymphocytic Leukemia | CLL, Relapsed | CLL, Refractory | Bruton Tyrosine Kinase Inhibitor

France
Insel Gruppe AG, University Hospital Bern
Sahajanand Medical Technologies Limited

Recruiting

Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation (MATRIX-2)

Atrial Fibrillation (AF) | Oral Anticoagulation | Percutaneous Coronary Intervention (PCI) | P2Y12 Inhibitor

Spain, France, Switzerland, United Kingdom, Germany, Belgium, Italy, Netherlands, Poland
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors (HAVEN 6)

Hemophilia A | Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor | Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor

United States, Netherlands, Belgium, France, Germany, South Africa, Spain, Canada, United Kingdom, Poland
Federation Francophone de Cancerologie Digestive

Recruiting

Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer (SIRTCI)

Metastatic Colorectal Cancer | MSS | pMMR | Immune Checkpoint Inhibitor | Internal Radiotherapy

France
Novo Nordisk A/S

Completed

Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

United States, Denmark, France, United Kingdom
Hospices Civils de Lyon

Not yet recruiting

Fertility and Pregnancy After Avelumab Treatment (FERTILAVE)

Immune Checkpoint Inhibitors | Gestational Trophoblastic Tumours

France
Central Hospital, Nancy, France

Completed

Distribution and Prognostic Impact of Oncogenic Drivers in Metastatic Lung Adenocarcinoma : a Retrospective Monocentric Study in Nancy University Hospital Center

Adenocarcinoma of Lung Stage IV | Adenocarcinoma of Lung, Response to Tyrosine Kinase Inhibitor in, Somatic

France
Pharvaris Netherlands B.V.

Completed

Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema (RAPIDe-1)

Hereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditions

Bulgaria, United States, Spain, Israel, Germany, Canada, Czechia, France, Hungary, Italy, Netherlands, Poland, United Kingdom
University Hospital, Caen

Completed

Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors. (KIWIS)

Chronic Myeloid Leukemia | Withdrawal Syndrome | Tyrosine Kinase Inhibitor

France
Novo Nordisk A/S

Completed

High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

France, United Kingdom, Spain, Israel, Poland, Turkey, Hungary
Novo Nordisk A/S

Active, not recruiting

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors (explorer8)

Haemophilia A Without Inhibitors | Haemophilia B Without Inhibitors

Spain, United States, Korea, Republic of, United Kingdom, Australia, Lithuania, France, Turkey, India, Estonia, Russian Federation, Ukraine, Mexico, Japan, South Africa, Serbia, Canada, Croatia, Algeria, Bosnia and Herzegovina, ... and more
German Breast Group
Pfizer; AGO Study Group; Breast International Group; NSABP Foundation Inc

Completed

A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery (PENELOPE-B)

Breast Cancer | Hormonreceptor Positive | Her2-normal | Postneoadjuvant Treatment With CDK 4/6 Inhibitor | CPS-EG Score

United States, Australia, Austria, Canada, France, Germany, Ireland, Japan, Korea, Republic of, Spain, United Kingdom
Novo Nordisk A/S

Completed

Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

France, United States, Sweden, Serbia, Turkey, United Kingdom, Malaysia, Brazil, Former Serbia and Montenegro, Japan, South Africa
Novo Nordisk A/S

Active, not recruiting

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors (explorer7)

Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

Spain, Korea, Republic of, India, Australia, United Kingdom, Russian Federation, Poland, Ukraine, Thailand, Mexico, United States, Turkey, Japan, South Africa, Serbia, France, Croatia, Denmark, Algeria, Bulgaria, Malaysia, Portugal, Slovaki... and more
Novo Nordisk A/S

Completed

Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors (ONE)

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

Saudi Arabia, Algeria, Turkey, Germany, Poland, Netherlands, Italy, Belgium, South Africa, United Kingdom, Sweden, Austria, Portugal, France, Czech Republic, Venezuela
Swedish Orphan Biovitrum
Cerner Enviza

Completed

rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A

Hemophilia A With Inhibitor

France, Ireland, Italy, Norway, Germany, Kuwait, Saudi Arabia, Switzerland
Daiichi Sankyo, Inc.
Plexxikon

Terminated

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

V600-mutated BRAF Unresectable Melanoma | V600-mutated BRAF Metastatic Melanoma | Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor

United States, Germany, France
Novo Nordisk A/S

Completed

PROPACT: Retrospective Prophylaxis Patient Case Collection (PROPACT)

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

Slovakia, Spain, Argentina, Germany, Croatia, Italy, Canada, United Kingdom, Ireland, Sweden, France, United States, Czech Republic, Switzerland
University Hospital, Bordeaux

Not yet recruiting

Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)

Alzheimer Disease | Cholinesterase Inhibitors

France
AstraZeneca
Hutchinson MediPharma (HMP)

Active, not recruiting

Savolitinib vs. Sunitinib in MET-driven PRCC.

Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Neoplasms by Site | Kidney Diseases | Carcinoma | Enzyme Inhibitors | Protein Kinase Inhibitors

United States, Italy, France, Korea, Republic of, Brazil, Russian Federation, Ukraine

Clinical Trials on PI3Kδ Inhibitor in France

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations